Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
84.688,71
-1,70%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amgen Inc (AMGN) Amgen Inc (AMGN) Notizie

AMGN

Amgen (AMGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMGN
DataOraFonteTitoloSimboloCompagnia
08/03/202512:00PR Newswire (US)AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITISNASDAQ:AMGNAmgen Inc
06/03/202502:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
04/03/202522:54PR Newswire (US)AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
01/03/202523:30PR Newswire (US)POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPSNASDAQ:AMGNAmgen Inc
28/02/202522:01PR Newswire (US)AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCENASDAQ:AMGNAmgen Inc
27/02/202516:10PR Newswire (US)Oncology Breakthroughs: How Cancer Research Is Advancing in 2025NASDAQ:AMGNAmgen Inc
21/02/202522:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMGNAmgen Inc
14/02/202522:18Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMGNAmgen Inc
14/02/202522:01PR Newswire (US)AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMITNASDAQ:AMGNAmgen Inc
07/02/202522:01PR Newswire (US)AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCENASDAQ:AMGNAmgen Inc
04/02/202522:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
04/02/202522:01PR Newswire (US)AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
01/02/202500:30PR Newswire (US)AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
29/01/202522:01PR Newswire (US)EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASENASDAQ:AMGNAmgen Inc
17/01/202515:01PR Newswire (US)FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCERNASDAQ:AMGNAmgen Inc
08/01/202522:01PR Newswire (US)AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
10/12/202422:30PR Newswire (US)AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
07/12/202416:00PR Newswire (US)BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)NASDAQ:AMGNAmgen Inc
05/12/202415:00PR Newswire (US)AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINANASDAQ:AMGNAmgen Inc
02/12/202422:00PR Newswire (US)AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
29/11/202422:30PR Newswire (US)AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCENASDAQ:AMGNAmgen Inc
26/11/202413:05PR Newswire (US)AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDYNASDAQ:AMGNAmgen Inc
26/11/202413:00PR Newswire (US)AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAMNASDAQ:AMGNAmgen Inc
20/11/202422:00PR Newswire (US)AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENTNASDAQ:AMGNAmgen Inc
14/11/202422:00PR Newswire (US)AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024NASDAQ:AMGNAmgen Inc
13/11/202421:27PR Newswire (US)MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRMNASDAQ:AMGNAmgen Inc
13/11/202411:00PR Newswire (US)AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATANASDAQ:AMGNAmgen Inc
08/11/202422:00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
08/11/202408:00PR Newswire (US)TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPSNASDAQ:AMGNAmgen Inc
31/10/202412:13IH Market NewsMicrosoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20%NASDAQ:AMGNAmgen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMGN

La tua Cronologia

AMEX
AAPX
T Rex 2X Long Apple Dail...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci